This article was prepared with the assistance of BioMedCom Consultants Inc, Montreal, Canada.
Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis†
Version of Record online: 31 MAR 2006
Copyright © 2006 by the American College of Rheumatology
Arthritis Care & Research
Volume 55, Issue 2, pages 287–293, 15 April 2006
How to Cite
Moreland, L. W., Genovese, M. C., Sato, R. and Singh, A. (2006), Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis & Rheumatism, 55: 287–293. doi: 10.1002/art.21838
- Issue online: 31 MAR 2006
- Version of Record online: 31 MAR 2006
- Manuscript Accepted: 8 SEP 2005
- Manuscript Received: 25 AUG 2004
- Wyeth Research
- Amgen, Inc.
- Rheumatoid arthritis;
- Quality of life;
- Health Assessment Questionnaire;
- Short Form 36
To assess the long-term impact of etanercept on fatigue in patients with recent-onset (mean duration 11 months) or established (mean duration 12 years) rheumatoid arthritis (RA).
Patients participating in either of 2 multicenter, randomized, double-blind clinical trials were included. In one trial, patients with recent-onset RA received either etanercept 25 mg twice weekly or methotrexate in a double-blind fashion for 12 months, then open label for 12 months. All patients then received open-label etanercept. In the second trial, patients with established RA received etanercept 25 mg or placebo twice weekly for 6 months in a double-blinded fashion, then open-label etanercept. Up to 46 months of followup data were included. Fatigue was measured regularly using the Health Assessment Questionnaire vitality domain.
Patients with recent-onset RA who received etanercept had a significantly faster improvement in fatigue than those receiving methotrexate in the first 2 months. Subsequently, patients receiving etanercept and methotrexate had 23–29% and 17–24% reductions in fatigue scores, respectively. In the group with established RA, patients who received etanercept had significantly greater reductions in fatigue than those receiving placebo during the blinded period. Patients initially receiving etanercept sustained a mean fatigue reduction of 25–36% for the entire followup. Patients achieving clinically meaningful improvement in fatigue were more likely to meet the American College of Rheumatology improvement criteria.
Etanercept therapy reduces fatigue in patients with recent-onset or established RA. Improvement in fatigue was sustained for up to 46 months, and correlated with other RA-relevant outcomes.